INNOCAN PHARMA (INNPF) SEC Filings

Innocan Pharma Corporation is offering up to 3,750,000 Units (each Unit: one common share and one warrant) and up to 3,750,000 pre-funded Units in an initial public offering priced between $5.00 and $6.00 per Unit. The warrants have an exercise price of $6.875 and expire five years from issuance. The prospectus gives effect to a 65-for-1 reverse share split and states common shares to be outstanding after this offering of 8,248,772 (or 8,811,272 if the underwriter exercises the over-allotment in full). Based on a $5.50 midpoint, net proceeds to the company are expected to be approximately $17.98 million (about $20.82 million with full over-allotment). The offering includes an option to purchase up to 562,500 additional common shares and/or warrants to cover over-allotments. Use of proceeds highlights R&D for human and veterinary LPT-CBD programs, manufacturing scale-up, and U.S. marketing.